The findings bring the phenomenon — and the controversy — of the latest new and powerful weight loss drugs to the youngest age group yet.
The new trial looked at liraglutide, the active ingredient used in two of Novo Nordisk’s older GLP-1 drugs: Saxenda, a weight loss drug, and Victoza, a diabetes drug.
So instead of looking at overall weight loss like in adult studies, they decided to focus more on BMI, which takes into account both weight and height.
A spokesperson for Novo Nordisk said that it has submitted an application to the Food and Drug Administration to expand the approval of liraglutide for weight loss in children ages 6 to 11.
Is 6 too young for a weight loss drug?
Persons:
Roy Kim, “, ” Kim, Claudia Fox, Fox, Eli Lilly, ”, liraglutide, ” Fox, Sarah Armstrong, ” Armstrong, comorbidities, it’s, ” Wegovy, Zepbound, Shauna Levy, ” Levy
Organizations:
New England, of Medicine, Novo Nordisk, Cleveland Clinic, Centers for Disease Control, University of Minnesota, BMI, Food and Drug Administration, American Academy of Pediatrics, Duke University, Tulane Bariatric Center
Locations:
liraglutide, Ozempic, Ohio, U.S, New Orleans